S
Steven G. Wong
Researcher at University of California, Los Angeles
Publications - 26
Citations - 19471
Steven G. Wong is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Cancer & Nivolumab. The author has an hindex of 12, co-authored 23 publications receiving 18687 citations.
Papers
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Dennis J. Slamon,William Godolphin,Lovell A. Jones,John A. Holt,Steven G. Wong,Duane E. Keith,Wendy J. Levin,Susan G. Stuart,Judy Udove,Axel Ullrich,Michael F. Press +10 more
TL;DR: The concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers, including breast and ovarian cancer, is supported.
Journal ArticleDOI
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer
Patsy Siok Hwa Soon,Lyndal J. Tacon,Anthony J. Gill,Christopher P. Bambach,Mark Sywak,Peter Campbell,Michael W. Yeh,Steven G. Wong,Roderick J. Clifton-Bligh,Bruce G. Robinson,Stan B. Sidhu +10 more
TL;DR: Findings indicate that deregulation of microRNAs is a recurring event in human adrenocortical carcinomas and that aberrant expression of miR-195 and miP-483-5p identifies a subset of poorer prognosis adrenocortsic carcinomas.
Journal ArticleDOI
Phase I Dose-escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jänne,D. S. Boss,D. Ross Camidge,Carolyn D. Britten,Jeffrey A. Engelman,Edward B. Garon,Feng Guo,Steven G. Wong,Jane Q. Liang,Stephen P. Letrent,Robert Millham,Ian Taylor,S. Gail Eckhardt,Jan H.M. Schellens,Jan H.M. Schellens +14 more
TL;DR: Both continuous and intermittent treatment schedules were well tolerated, and encouraging signs of antitumor activity were observed in gefitinib/erlotinib treated NSCLC patients.
Journal ArticleDOI
Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.
TL;DR: Differential hybridization was used to identify genes whose expression levels are altered in cells overexpressing this receptor, and up-regulation of two of the identified cDNAs was confirmed in human breast cancer specimens in association with HER-2/ neu overexpression.